Global Non-Small Cell Lung Cancer Market Research Report 2017 tracks the major market events including product launches, technological developments, mergers & acquisitions, and the innovative business strategies opted by key market players. Along with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities and challenges in the Copper Strips market. This research report offers in-depth analysis of the market size (revenue), market share, major market segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges.
Leading companies operating in the global Non-Small Cell Lung Cancer market profiled in the report are F. Hoffmann-La Roche, Pfizer Inc., Astra Zeneca, Eli Lilly.
On the basis of application the global Non-Small Cell Lung Cancer market is segmented into Chemotherapy and Radiation, Chemotherapy Before Other Treatments (Neoadjuvant Treatment), Targeted Treatments, and Immunotherapy. For comprehensive understanding of market dynamics, the global Non-Small Cell Lung Cancer market is analyzed across key geographies namely Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.
Inquire for free sample copy at: https://www.marketinsightsreports.com/reports/120484682/non-small-cell-lung-cancer-market-global-briefing-2017-including-chemotherapy-and-radiation-chemotherapy-before-other-treatments-neoadjuvant-treatment-targeted-treatments-and-immunotherapy-covering-f-hoffmann-la-roche-pfizer-inc-astra-zeneca-eli-lilly/inquiry
The non-small cell lung cancer drugs market cover drugs that treat conditions related to lung cancer. These indications include adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and large cell neuroendocrine tumors. Some of the major drugs in this market are Erlotinib, Afatinib (Gilotrif), Gefitinib (Iressa), Bevacizumab (Avastin), Crizotinib (Xalkori), and Ceritinib (Zykadia). Based on the treatment type, the market is segmented into four segments: Chemotherapy and Radiation; Chemotherapy Before Other Treatments (Neoadjuvant Treatment); Targeted Treatments; and Immunotherapy.
The global non-small cell lung cancer market was estimated to be around $6.6 billion as of 2016. The global non-small cell lung cancer made up around 6% of the overall oncology drugs market in 2016. The non-small cell lung cancer market was the sixth largest market in the global oncology drugs market in 2016.
Continous approvals from regulatory bodies such as FDA in the US and EMA in Europe is one of the major trend in this market. For instance, in 2015, FDA approved gefitinib drug for for its commercialization in the US market. This drug is used in the treatment of non small cell lung cancer. In 2014, FDA approved Ceritinib (Zykadia) drug for its commercialization in the US market. This drug is used in the treatment of metastatic ALK-positive lung cancer. In 2013, FDA approved Afatinib (Gilotrif) drug that is used in the initial treatment of metastatic non small cell lung cancer in patients with the same EGRF gene mutations.
15 Chapters are covered in this Report to deeply display the global Non-Small Cell Lung Cancer market.
Chapter 1, to describe Non-Small Cell Lung Cancer Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyse the top manufacturers of Non-Small Cell Lung Cancer, with sales, revenue, and price of Non-Small Cell Lung Cancer, in 2016and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Non-Small Cell Lung Cancer, for each region, from 2012 to 2017;
Chapter 5, 6, 7,8 and 9, to analyse the key regions, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;
Chapter 12, Non-Small Cell Lung Cancer market forecast, by regions, type and application, with sales and revenue, from 2017to 2022;
Chapter 13, 14 and 15, to describe Non-Small Cell Lung Cancer sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.
Available complete report of this research with TOC and List of Figures at: https://www.marketinsightsreports.com/reports/120484682/non-small-cell-lung-cancer-market-global-briefing-2017-including-chemotherapy-and-radiation-chemotherapy-before-other-treatments-neoadjuvant-treatment-targeted-treatments-and-immunotherapy-covering-f-hoffmann-la-roche-pfizer-inc-astra-zeneca-eli-lilly
The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.
This report provides in-depth analysis of the Non-Small Cell Lung Cancer and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2022, considering 2016 as the base year. It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. This study also provides key insights about market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading players. It profiles leading players in the global Non-Small Cell Lung Cancer market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans Key companies covered as a part of this study include. Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, market expansion, and marketing tactics. The global Non-Small Cell Lung Cancer market report caters to various stakeholders in this industry, including investors, device manufacturers, distributors and suppliers for Non-Small Cell Lung Cancer equipment, government organizations, research and consulting firms, new entrants, and financial analysts. Various strategy matrices used in analyzing the Non-Small Cell Lung Cancer market would provide stakeholders vital inputs to make strategic decisions accordingly.
MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
+1 (704) 266-3234 | email@example.com
Connect With us on: